Production (Stage)
CASI Pharmaceuticals, Inc.
CASI
$1.33
-$0.51-27.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -53.28% | 71.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.28% | 71.38% | |||
| Cost of Revenue | -74.12% | 170.22% | |||
| Gross Profit | 12.11% | -20.20% | |||
| SG&A Expenses | 0.03% | 12.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -150.00% | -- | |||
| Total Operating Expenses | -35.93% | 61.92% | |||
| Operating Income | 17.17% | -52.80% | |||
| Income Before Tax | 25.19% | -71.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.19% | -71.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.19% | -71.17% | |||
| EBIT | 17.17% | -52.80% | |||
| EBITDA | 18.02% | -64.64% | |||
| EPS Basic | 7.52% | -36.69% | |||
| Normalized Basic EPS | -4.42% | -2.71% | |||
| EPS Diluted | 7.60% | -36.82% | |||
| Normalized Diluted EPS | -4.42% | -2.71% | |||
| Average Basic Shares Outstanding | -19.11% | 25.22% | |||
| Average Diluted Shares Outstanding | -19.11% | 25.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||